RCM
REGN icon

Reynolds Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Reynolds Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,100
Closed -$1.14M – 148
2015
Q4 		$1.14M Buy
2,100
+600
+40% +$325K 1.24% 19
2015
Q3 		$698K Buy
1,500
+500
+50% +$269K 0.87% 33
2015
Q2 		$510K Sell
1,000
-1,000
-50% -$488K 0.5% 58
2015
Q1 		$903K Buy
2,000
+400
+25% +$170K 0.79% 21
2014
Q4 		$656K Buy
1,600
+100
+7% +$39.3K 0.55% 47
2014
Q3 		$541K Buy
+1,500
New +$503K 0.52% 52
2014
Q2 		– Sell
-1,200
Closed -$360K – 383
2014
Q1 		$360K Hold
1,200
– – 0.23% 167
2013
Q4 		$330K Sell
1,200
-200
-14% -$57.5K 0.19% 214
2013
Q3 		$438K Buy
1,400
+200
+17% +$52.6K 0.28% 108
2013
Q2 		$270K Buy
+1,200
New +$279K 0.2% 220

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Reynolds Capital Management's REGN Position: Q1 2016 in Review

Reynolds Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2016, closing a stake of 2,100 shares — an estimated $1.14M sold.

Reynolds Capital Management first reported a position in REGN in Q2 2013 and held it in 10 quarters. The position peaked at $1.14M in Q4 2015. 550 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

  • Reynolds Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Reynolds Capital Management sold 2,100 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $1.14M.
  • Reynolds Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • Reynolds Capital Management's Regeneron Pharmaceuticals position peaked at $1.14M in Q4 2015.
  • 550 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Reynolds Capital Management's 13F filing for Q1 2016, filed 13 May 2016.